GlycoVaxyn

Company developing a broad portfolio of bioconjugate vaccines to prevent common bacterial infections using its proprietary glycoprotein technology.

Launch date

Apr 2004

Employees

Market cap

Enterprise valuation

€173m (Public information from Feb 2015)

Company register number CH-020.3.028.196-4

Zurich Canton of Zürich (HQ)

Revenues, earnings & profits over time

EUR	2015	2016	2017	2018
Revenues	4.6m	4.7m	4.3m	4.4m
% growth	-	1 %	(8 %)	4 %

Source: Dealroom estimates

Date	Investors	Amount	Round
Jan 2004	ETH Zurich	N/A	Spinout
Jul 2006	Index Ventures Sofinnova Partners	$800k	Series A
Jul 2007	N/A	€6.9m	Series A
Mar 2009	Index Ventures Sofinnova Partners Andera Partners	$21.3m	Series B
Feb 2015	GSK	$190m Valuation: $190m	Acquisition
Total Funding		€27.0m

Tech stackLearn more about the technologies and tools that this company uses.

Financials